Background/Aims: The direct implication of low density lipoprotein receptor (LDLR) in hepatitis C virus (HCV) infection of human hepatocyte has not been demonstrated.
Introduction
Hepatitis C virus (HCV) infection represents a serious health problem worldwide (1) . HCV is a positive RNA strand enveloped virus classified as a Hepacivirus within the Flaviviridae family (2, 3) . Hepatocytes represent the major site of replication of HCV, although this virus has been shown to infect other cell types (3) (4) (5) . The mechanism by which HCV binds to and enters hepatocytes is not fully understood. Several in vitro models have been used to identify and characterize the HCV receptor, including cell lines infected with either plasma or serum from infected patients or virus-like particles (HCV-LP) expressed in insect systems (6) , VSV/HCV pseudotype virus (7, 8) , or pseudotyped retroviral particles (HCVpp) (9) (10) (11) . More recently productive Huh-7-based cellular systems (HCVcc) have been described (12) (13) (14) (15) . Several receptor candidates have been identified, including CD81 (16), scavenger receptor-BI (17) , DC-SIGN and/or L-SIGN (18) , asialoglycoprotein receptor (19) and low-density lipoprotein receptor (LDLR) (20) (21) (22) .
LDLR is a membrane glycoprotein that controls the primary pathway through which cholesterol enters the cells. The N-terminal ligand binding domain spans over residues 1-292 arranged in 7 repeats. Each repeat contains 6 S-S linked cysteines (23, 24) . The physiological ligand LDL contains a single copy of apolipoprotein B-100 and carries 65-70% of plasma cholesterol. The receptor also binds apolipoprotein Econtaining lipoproteins such as very low-density lipoproteins (β-VLDL). LDLR has been suspected to play a role in HCV infection on the basis of the well documented interaction between HCV and lipoproteins (25) (26) (27) . Ultracentrifugation of infected plasma on density gradients revealed two compartments in which HCV is abundant.
The first one (1.25 g/ml) contains poorly infectious particles linked to immunoglobulins. The second (1.06 g/ml) contains infectious lipoviroparticles that are rich in triglycerides, and apolipoprotein B and E. Further observations supporting a role for LDLR in HCV infection came from analysis of the effects of lovastatin (22) , anti-LDL antibodies (8, 20, 21, 28) , LDLR genetic deficiency (21, 25, 28) and LDLR ectopic expression (21) .
However, all these studies have been carried out using cell lines or virus particles that do not mimic the natural infection. In contrast, primary cultures of highly differentiated human hepatocytes (29-32, 33, 34) are likely to represent the most physiologically relevant model to investigate serum-derived HCV infection. Indeed,
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previous studies have shown that human hepatocytes are sensitive to infection by HCV or hepatitis delta virus and permissive to their genome replication (35) (36) (37) .
The present study was undertaken to determine whether LDLR plays a role in the infection of these cells by HCV. For this purpose, specific tools were developed including recombinant soluble LDLR peptides and monoclonal antibodies.
Hepatocytes were infected with HCV-positive sera in the absence or presence of LDLR peptides and anti-LDLR antibodies. Cellular levels of LDLR were modulated with squalestatin or 25-hydroxycholesterol. Based on the analysis of viral genome expression, the results suggest that LDLR plays a role in an early step of infection of human hepatocytes by serum-derived HCV virions.

Materials and methods
Cells
Hepatocytes were isolated from liver lobectomy specimens resected for medical reasons unrelated to our research program, as approved by the National Ethics Committee. Primary cultures of human hepatocytes were prepared from twenty two different patients free of HCV, HBV and HIV markers (Table 1) , and cultured as described (31, 34) . CHO-K1 and HepG2 cells were cultured in MEM supplemented with 5% fetal calf serum (FCS), 2mM glutamine, 100U/ml penicillin and 100μg/ml streptomycin, and DMEM supplemented with 10% FCS, 100U/ml penicillin and 100μg/ml streptomycin, respectively.
HCV-positive serum samples
HCV-positive serum samples (free of HBV and HIV markers) used to infect hepatocytes (Table 2) were prepared from blood collected for medical and biological diagnosis on HCV chronic carriers before treatment with interferon-ribavirine, and characterised and stored as described (35) .
In vitro infection of hepatocytes and treatments
The procedure previously described was used here (35, 36) . Hepatocytes were pre-treated or not with either: 0.62 to 620 nM of r-shLDLR4-166, r-shLDLR4-292 or u-shLDL4-166, or 2 to 8 µg/ml of mAb12.6, mAb28 and mAb29.8, for thirty minutes before and during infection. In some experiments, hepatocytes were treated with 62 nM r-shLDLR4-292 either at the time of infection (T0) or 0.5, 2 or 8 hours later, or for 24 hours with either 10 to 80 µM squalestatin (SQ, Sigma St Louis MO) or 25-hydroxycholesterol (25-OHC, Sigma).
Detection of HCV RNA and quantification by real-time PCR
Total cellular RNA was purified and intracellular HCV RNA strands were analyzed by strand-specific rTth/RT-PCR and quantitative RT-PCR as described (35, 36, 38, 39) , and normalized to GAPDH RNA. In some experiments, cells were treated with 5 mM suramin for 30 minutes, before harvest and quantification of HCV RNA. 
Expression and purification of soluble LDLR
Monoclonal antibodies against r-shLDLR4-292
Peptide r-shLDLR4-292 in Complete Freund's Adjuvant was injected into 7-week-old female mice. After boosting successsively with 10 and 50 µg/mouse of immunogen, sera were tested by ELISA. Best responders were selected and hybridoma generated. Monoclonal antibodies (mAbs) generated by clones 12.6, 28 and 29.8 were purified by chromatography on Protein G column and identified as IgG1.
Expression of LDLR mRNA
One microgram of total RNA was reverse transcribed, using random hexamer primers and MMLV reverse transcriptase (Invitrogen, Carlsbad, CA). cDNA was analysed by real-time PCR, using forward 5'-ACTGGTGTGAGAGGACCACC-3', and reverse 5'-CAAAGGAAGACGAGGAGCAC-3' LDLR primers.
Preparation of lipoproteins
Lipoproteins were isolated from normolipidemic donor plasmas by ultracentrifugation and ionidated as described (40) . More than 97% of radioactivity was associated with protein.
Treatments of hepatocytes with BODIPY FL LDL
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Hepatocytes, pre-treated or not with 10-80 µM SQ or 25-OHC, were exposed to 3-6 µg/ml BODIPY FL LDL (Molecular Probe, L-3483) for 2-48 hours in the absence or presence of a 25-fold excess of unlabeled LDL. 
125 I-lipoprotein binding to and entry into CHO, HepG2 cells and hepatocytes
CHO
LDLR expression and activity in primary human hepatocytes
Sterol regulatory element-binding proteins (45) confirmed these results (Fig. 1B) . Thus, in cultured hepatocytes, LDLR is functional and regulated as expected by the cholesterogenic status of cells.
Effect of r-shLDLR peptides and monoclonal and polyclonal antibodies against rshLDLR4-292
Specific tools were developed to evaluate LDLR implication in HCV infection.
These included recombinant soluble LDLR peptides r-shLDLR4-331, r-shLDLR4-292, and r-shLDLR4-166 or urinary u-shLDLR4-166, and monoclonal antibodies (mAb) generated against r-shLDLR4-292: mAb12.6, mAb28 and mAb29.8 ( Fig. Suppl-5 ).
Both r-shLDLR4-292 and r-shLDLR4-331 equally bound LDL, while r-shLDLR4-166
and u-shLDLR4-166 did not. When compared to LDL, VLDL bound moderately to rshLDLR331, while HDL did not. HDL entry was not inhibited, while inhibition of VLDL entry was intermediate ( mAb28 exhibited the strongest inhibitory effect on LDL binding to r-shLDLR4-331, followed by mAb12.6 and mAb29.8 ( Fig. Suppl-8) . Consistently, mAb28 strongly inhibited LDL entry in HepG2 cells while inhibition mediated by mAb12.6 and mAb29.8 was weaker (Fig. 3A) .
Competition effect of mAb12.6, mAb28 and mAb29.8, and an anti-LDLR polyclonal antibody known to inhibit LDL entry into human fibroblasts (kindly provided by John Chapman, Paris) was tested during hepatocyte infection. mAb28 markedly
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inhibited accumulation of both replicative (Fig. Suppl-9 ) and genomic ( Fig. 3B ) strand (>90%), while mAb12.6 and mAb29.8 produced approximately 66% inhibition at the greater concentration. Interestingly, the inhibitory effect of mAbs on infection paralleled their inhibitory effect on LDL binding to LDLR and cellular entry. The polyclonal anti-LDLR antibody was less potent than mAb28 but produced marked inhibition as well. Mouse IgG-1 and anti-CD29 (integrin-β1) monoclonal antibody (Immunotech, clone K20), used as controls, had no significant effect (Fig 3C) . Thus, antibodies that inhibit LDL binding to LDLR also inhibit HCV infection. Whether the antibodies compete with HCV-lipoviroparticles binding or inhibit receptor internalisation is unknown.
Since LDL is also a high-affinity ligand for SR-BI, it was pertinent to evaluate the effect of r-shLDLR peptides and monoclonal antibodies on SR-BI-mediated entry of HDL into the cells. Neither r-shLDLR292, r-shLDLR166, mAbs (28, 12.6 or 29.8), SQ or 25OHC had significant effect ( Fig. Suppl-10 ), arguing in favor of the specificity of their effects.
Effect of LDL and HDL
Hepatocytes were infected with HCV-positive serum in the absence or presence of 1.5-150 nM LDL; 15-1500 nM HDL2 or HDL3 were used as control since these lipoproteins use a distinct receptor, SR-BI. LDL produced a strong inhibitory effect at 150 nM on both replicative (Fig. Suppl-11 ) and genomic (Fig. 4) strand while HDL3-mediated inhibiton was only observed at 1500 nM, and HDL2 had no effect.
Effect of SQ and 25OHC
Since SQ and 25OHC modulate LDLR expression, we tested whether pretreatment of hepatocytes with these compounds modulate HCV infection.
Interestingly, accumulation of both replicative (Fig. Suppl-12 ) and genomic ( LDLR is expressed in many cell types and not just in hepatocytes. Moreover, expressing this receptor ectopically does not restore cell responsiveness to HCV (9) (10) (11) . This indicates that LDLR is probably not the sole player to mediate HCV entry.
Indeed, other receptors, including CD81, SR-BI, the asialoglycoprotein receptor, and DC/L-SIGN have also been implicated in HCV cell entry (16, (17) (18) (19) . In particular, CD81 and SR-BI are known to interact with HVR1 region of E2, and it has been emphasized that all cells permissive to HCV infection express LDLR, CD81 and SR-BI (9). However, none of these receptors, expressed alone or in combination, define permissiveness to infection (11) . The current observation that high concentrations of HDL3 inhibit HCV genome replication in human hepatocytes (Fig. 4) In conclusion, the current results, obtained with highly differentiated normal human hepatocytes inoculated with serum-derived HCV virons, support the notion that LDLR plays a role in an early step of virus entry. Other membrane proteins are likely to be responsible for the unique capacity of HCV to bind and enter hepatocytes.
Testing the role of these proteins including CD81 and SR-BI is currently under investigation using this primary hepatocyte culture system. 
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